


KRAS mutations in non-small cell lung cancers are prognostic of poor survival.2 KRAS G120 is the most common, positive in an estimated 13% of patients with NSCLC.1



**KRAS TESTING IS RECOMMENDED** IN ADVANCED NSCLC PATIENTS.<sup>2</sup> – NCCN

KRAS: Kirsten rat sarcoma; NCCN: National Comprehensive Cancer Network

References: 1. Biernacka A et al. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. *Cancer Genet.* 2016;209(5):195–198. 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. Version 8.2020 – September 15, 2020. NCCN.org.

© 2020 Amgen Inc. All rights reserved.











